BOSTON, LAUSANNE & LJUBLJANA, Slovenia:
Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach
Genialis (http://www.genialis.com), a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made. Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health Ventures and several Angels. Ita Lu of Taiwania and Hamzeh Abdul-Hadi of Debiopharm will join Genialis’ Board of Directors.
Genialis is developing next-generation patient classifiers using machine learning and high-throughput omics data to capture underlying disease biology and predict how patients will likely respond to targeted therapies. The company will use the funds from the Series A to expand its proprietary ResponderID(™) platform and build out its comprehensive collection of clinically validated biomarker models to provide pinpoint diagnoses for virtually every cancer patient. To date, Genialis has used ResponderID in collaboration with biopharma to analyze clinical trial data and inform future trial designs for numerous investigational drugs. Genialis also supports the commercialization of next-gen biomarker assays with several leading diagnostic firms.
“With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” says Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We chose to focus initially on biomarkers that improve the efficiency of drug development, that ensure the right patient gets the right medicine, and make an impact on real people’s lives in a shorter period of time.”
ResponderID is a machine learning platform for clinical and translational research, built from years of experience working with partners across the industry and advanced internal R&D. ResponderID yields new biomarkers for drug development and discovery programs, as well as diagnostic tests. ResponderID can read the status of virtually any NGS-based biomarker, including bespoke and proprietary signatures, from a single assay. The resulting output provides clinical and translational researchers with a comprehensive molecular portrait of patient disease phenotype enabling the most informed decision-making possible.
“ResponderID, Genialis’ predictive biomarker platform, enables precision medicine by identifying patients that are most likely to respond to treatments. Its use in drug development will optimize study designs and improve chances of clinical trials success, driving much-needed productivity gains for pharma R&D and accelerating the time to market for promising new drugs,” said Hamzeh Abdul-Hadi, Investment Director at Debiopharm Innovation Fund.
Last year, ten publications and poster presentations at major scientific conferences featured results generated with ResponderID, including AACR (https://www.genialis.com/2022/04/11/genialis-and-oncxerna-co-present-their-latest-findings-implicating-the-xerna-tme-panel-as-a-pan-cancer-diagnostic/), ESMO (https://www.genialis.com/2022/09/30/a-novel-tumor-microenvironment-patient-classifier-for-gastroesophageal-cancer/), and SITC (https://www.genialis.com/2022/11/30/xernatm-tme-panel-is-a-predictive-biomarker-in-lung-cancer/). Genialis also co-authored a paper in the Journal of Clinical Oncology (https://ascopubs.org/doi/10.1200/JCO.21.01801) describing OncXerna’s navicixizumab ph1b trial, including retrospective analysis with the Xerna TME Panel.
“Genialis is leading the collision of biology and AI. Our approach is biology first, but with a deep commitment to getting the data science right. Thus, we only succeed as a team that understands both worlds,” said Miha Stajdohar, Ph.D., co-founder and CTO of Genialis. “This capital brings together a global syndicate of clinical oncology and deep tech experts and will allow us to grow our in-house capabilities in multiple disciplines.”
Genialis is growing its teams in both the U.S. and Slovenia across business, operations, life science, and data science functions and expanding its advisory boards. The company is also investing in R&D collaborations with several leading cancer centers, hospital groups, and clinical academic labs.
“Genialis has an impressively clear vision, compelling AI-drug discovery biomarker models, and robust underlying science supporting their platform. We look forward to working closely with the Genialis team to explore and pursue growth opportunities in this burgeoning space,” said Ita Lu, Managing Partner, Taiwania Capital Management.
Genialis will present a poster at the Genomics in Precision Oncology Xchange (https://www.hub-xchange.com/genomics-in-precision-oncology-east-coast-2023/) on April 5, 2023, in Boston. The next day, they will host a roundtable discussion at the Oncology Companion Diagnostics Xchange (https://www.hub-xchange.com/oncology-companion-diagnostics-xchange-east-coast-2023/), also in Boston. Genialis is attending AACR 2023 from April 14-19, 2023 (https://www.aacr.org/meeting/aacr-annual-meeting-2023/), in Orlando, Fla., where it is co-presenting a poster with OncXerna Therapeutics and Regeneron Pharmaceuticals. For more information on ResponderID, please email email@example.com or visit www.genialis.com.
Genialis is a computational precision medicine company unraveling complex biology to find new ways to address disease. ResponderID™, Genialis’ machine-learning-driven disease modeling platform, delivers actionable biomarkers and optimally positions novel drugs to accelerate translational research, streamline drug development and ensure the best possible clinical care. Genialis is trusted by pharma and diagnostics partners, and together, we bring precision to medicine.
About Taiwania Capital
Taiwania Capital is a venture capital firm founded in August 2017 by the National Development Fund of the Executive Yuan of Taiwan and private enterprises. It is a national venture capital firm that manages six funds mainly focused on technology and biotechnology. As of the end of 2022, the total size of funds reached US$865 million. The firm has invested in 61 enterprises and startups at home and abroad, five of which have been listed in Taiwan and America. Taiwania Capital has assisted fourteen foreign enterprises in starting partnerships or building plants in Taiwan. Taiwania Capital has offices in Taiwan, the United States, and Central and Eastern Europe. https://en.taiwaniacapital.com/
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017 Debiopharm has invested in 20 AI and digital health companies, typically leading the investment rounds.
|Textquelle:||Debiopharm International SA, übermittelt durch news aktuell|
- truu ist “Arbeitgeber der Zukunft” - 7. Juni 2023
- Deutscher Raiffeisentag 2023 wagt Blick in die Zukunft - 7. Juni 2023
- Vorstellung einer “Wireless Revolution” für Solarinstallationen - 7. Juni 2023